Enrolment options
Dr. Oğuz Abdullah Uyaroğlu,
Department of Internal Medicine,
Division of Internal Diseases,
Hacettepe University Faculty of Medicine,
Ankara, Turkiye
Summary
Pulmonary fibrosis is one of the more severe and frequently reported COVID-19 sequela. In a recent meta-analysis; the prevalence of post-COVID-19 pulmonary fibrosis (PCPF) is ranging from 25.5% to 84.15% without a significant gender difference. Patients with PCPF more commonly suffer from persistent symptoms of dyspnea (50%), cough (31.6%), chest pain (30.5%), fatigue (80%), and myalgia (58.3%). The pathogenic progression of PCPF has been yet to be fully illuminated; however, it is thought to be multifactorial. To date, there is no proven treatment for PCPF, which makes the condition even more concerning. The complaint of newly developing or increasing dyspnea after active COVID-19 should be a warning in terms of fibrosis. Here, an interesting case diagnosed with PCPF during his recovery period is presented.
This e-learning module was developed by: EFIM Academy
Target Audience
This e-learning module is suitable for internists, but is also built to serve internal medicine trainees and physicians in other disciplines, as well as health care professionals who have an interest in infectious diseases.
Additional information
- This e-learning module is designed to last approximately half an hour in total
- All authors and the e-learning module editors have declared that they have no conflicts of interest in relation to the material in this e-learning module
- The production of this e-learning module was funded entirely by the EFIM Academy. No external sponsorship was received
- The material used in this e-learning module was prepared in 2022.
- Unless otherwise stated, all display items are provided courtesy of the e-learning module authors
- Learners are invited to test their knowledge in the e-learning module via 4 questions
- The e-learning module has a pass mark of 75%. Those scoring less than the required pass mark are encouraged to revisit the e-learning module and retake the assessment

Course enrollment
| Duration | 30 minutes |
| Language | EN |
| Release date | Wednesday, 31 May 2023 |